COMPANY

Starton Therapeutics

Keywords: oncology blood cancers drug delivery Multiple Myeloma

Location: Paramus, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Oct 2, 2023 Trial start Phase 1/Phase 2: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) source ↗

May 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) · NCT06087653

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06087653	Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)	Phase 1/Phase 2	Recruiting	Oct 2, 2023	May 31, 2027 (estimated)